Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE cohort.

Swerdlow, Anthony J; Cooke, Rosie; Beckers, Dominique; Butler, Gary; Carel, Jean-Claude; Cianfarani, Stefano; Clayton, Peter; Coste, Joël; Deodati, Annalisa; Ecosse, Emmanuel; Hokken-Koelega, Anita C S; Khan, Aysha J; Kiess, Wieland; Kuehni, Claudia E; Flück Pandey, Christa Emma; Pfaffle, Roland; Sävendahl, Lars; Sommer, Grit; Thomas, Muriel; Tidblad, Anders; ... (2019). Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE cohort. Journal of clinical endocrinology and metabolism, 104(3), pp. 658-664. Endocrine Society 10.1210/jc.2018-01133

[img]
Preview
Text
Swerdlow JClinEndocrinolMetab 2018.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (286kB) | Preview

Context There has been concern that growth hormone (GH) treatment of children might increase meningioma risk. Results of published studies have been inconsistent and limited. Objective To examine meningioma risks in relation to GH treatment. Design Cohort study with follow-up via cancer registries and other registers. Setting Population-based. Patients A cohort of 10,403 patients treated in childhood with recombinant GH (r-hGH) in 5 European countries since this treatment was first used in 1984. Expected rates from national cancer registration statistics. Main Outcome Measures Risk of meningioma incidence. Results During follow-up 38 meningiomas occurred. Meningioma risk was greatly raised in the cohort overall (SIR=75.4; 95% confidence interval (CI) 54.9-103.6), as a consequence of high risk in subjects who had received radiotherapy for underlying malignancy (SIR= 658.4; 95% CI 460.4-941.7). Risk was not significantly raised in patients who did not receive radiotherapy. Risk in radiotherapy-treated patients was not significantly related to mean daily dose of GH, duration of GH treatment or cumulative dose of GH. Conclusions Our data add to evidence of very high risk of meningioma in patients treated in childhood with GH after cranial radiotherapy, but suggest that GH may not affect radiotherapy-related risk, and that there is no material raised risk of meningioma in GH-treated patients who did not receive radiotherapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine

UniBE Contributor:

Kühni, Claudia; Flück Pandey, Christa Emma and Sommer, Grit

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0021-972X

Publisher:

Endocrine Society

Language:

English

Submitter:

Tanya Karrer

Date Deposited:

12 Sep 2018 16:37

Last Modified:

24 Oct 2019 04:24

Publisher DOI:

10.1210/jc.2018-01133

PubMed ID:

30137467

BORIS DOI:

10.7892/boris.119694

URI:

https://boris.unibe.ch/id/eprint/119694

Actions (login required)

Edit item Edit item
Provide Feedback